Cargando…
A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress
Receptor tyrosine kinase (RTK), c-Met, is overexpressed and hyper active in renal cell carcinoma (RCC). Most of the therapeutic agents mediate cancer cell death through increased oxidative stress. Induction of c-Met in renal cancer cells promotes the activation of redox-sensitive transcription facto...
Autores principales: | Rawat, Laxminarayan, Balan, Murugabaskar, Sasamoto, Yuzuru, Sabarwal, Akash, Pal, Soumitro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628632/ https://www.ncbi.nlm.nih.gov/pubmed/37898101 http://dx.doi.org/10.1016/j.redox.2023.102945 |
Ejemplares similares
-
A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape
por: Sabarwal, Akash, et al.
Publicado: (2020) -
Novel Honokiol-eluting PLGA-based scaffold effectively restricts the growth of renal cancer cells
por: Hamedani, Yasaman, et al.
Publicado: (2020) -
Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth
por: Balan, Murugabaskar, et al.
Publicado: (2017) -
Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1
por: Chakraborty, Samik, et al.
Publicado: (2019) -
Cabozantinib‐induced renal thrombotic microangiopathy
por: La Manna, Gaetano, et al.
Publicado: (2017)